Abstracts

732 – Despite Increasing Use of INIs to Treat HIV Infection, Resistance to This Class Remains Stable

Background Since the beginning of HIV treatment, changes in the use of antiretroviral (ARV) drugs have often led to changes in HIV resistance mutation patterns. The integrase inhibitor (INI) class has benefited from many developments: first raltegravir (RAL) and elvitegravir (EVG), followed by dolutegravir (DTG), cabotegravir (CAB) and bictegravir (BIC). The aim of this study…

680 – Impact of Oral Lead-In on PK and Virologic Outcomes in People With HIV Transitioning to CAB+RPV LA

Background For people with HIV (PWH) on antiretroviral therapy (ART), transitioning to bimonthly long-acting (LA) injectable cabotegravir (CAB) plus rilpivirine (RPV) can be done either directly (non-OLI) or after an optional one-month oral lead-in (OLI). Recent data suggest lower CAB trough concentrations (Ctrough) with non-OLI initiation. This study aimed to assess pharmacokinetics (PK) and virological…

739 – Real-World Robustness of B/F/TAF at Virologic Failure in the ANRS-CO3-AquiVIH-NA Cohort

Background Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is a high potent and simplified antiretroviral therapy (ART) regimen as shown by clinical trials. However, real-world evidence in individuals experiencing a virologic failure (VF) remains limited. We investigated the virological outcomes in participants who experienced VF after switching to B/F/TAF. Methods We conducted a retrospective study using data from the…

738 – Bictegravir + Lenacapavir: Baseline and Week 48 Resistance in ARTISTRY-1 Phase II

Background ARTISTRY-1 is a Phase 2/3 study evaluating the safety and efficacy of the complete regimen of the capsid inhibitor lenacapavir (LEN) given with the integrase strand-transfer inhibitor (INSTI) bictegravir (BIC) compared to remaining on a complex multi-tablet regimen. Virologically suppressed participants with no known INSTI resistance mutations were enrolled in the Phase 2 portion. At…

736 – Resistance Analysis of Weekly Islatravir Plus Lenacapavir in People With HIV at 48 Weeks

Background Islatravir (ISL), a nucleoside reverse transcriptase (RT) translocation inhibitor, and lenacapavir (LEN), a capsid (CA) inhibitor, have pharmacokinetic profiles supportive of once-weekly (QW) oral dosing. GS-US-563-6041 (NCT05052996) is a Phase 2, open-label study evaluating QW ISL+LEN in virologically suppressed people with HIV-1. At Week (W) 48, ISL+LEN maintained high rates (94.2%) of viral suppression (VS;…

699 – Characteristics and Treatment Outcomes of People With HIV Prescribed Fostemsavir in the Trio Cohort

Background Fostemsavir [FTR] is approved for use with other active antiretrovirals [ARVs] for treatment of heavily treatment-experienced people with HIV [PWH] and multi-drug resistance [MDR]. We described characteristics and treatment outcomes among PWH prescribed FTR in a real-world setting in the US.  Methods PWH initiating FTR from July 2020 (FDA approval) to June 2023 identified…

708 – A Strategy for Durable AAV-Vectored bNAb Expression in Adult Rhesus Macaques

Background Sustained expression of adeno-associated virus (AAV)-vectored anti-HIV-1 broadly neutralizing antibodies (bNAbs) could prevent and treat HIV-1 infection. However, durable expression of AAV-vectored bNAbs in vivo is limited by host immune responses, impeding efficacy studies in preclinical nonhuman primate (NHP) models. Programmed cell death protein (PD)-1 is an immune checkpoint protein on T cells that…

692 – A5359: Decreasing Oral Induction Duration in Support of LAI ART Use With Hardly Reached Populations

Background Large randomized clinical trials of investigational agents in people with HIV (PWH) routinely exclude participants with adherence challenges. ACTG 5359, a phase III, prospective, randomized, open-label trial comparing long acting cabotegravir + rilpivirine (LAI) vs. oral standard of care (SOC) ART in PWH with a history of suboptimal adherence (persistent HIV-1 RNA >200 c/mL…

684 – What Do Early Adopters of Long-Acting Injectable Cabotegravir/Rilpivirine Think About It?

Background Little is known about experiences with long-acting injectable cabotegravir/rilpivirine (LA-CAB/RPV) in underserved people with HIV (PWH), particularly PWH initiating with viremia due to adherence challenges. Methods In a cross-sectional survey of PWH with ≥3 injections at Ward 86 (San Francisco), Grady Ponce de Leon (Atlanta), and the University of Chicago, we assessed treatment satisfaction…

683 – Why Do People With HIV Stop Long-Acting Injectable Cabotegravir/Rilpivirine and What Happens?

Background We sought to examine reasons for discontinuation of long-acting injectable cabotegravir/rilpivirine (LA-CAB/RPV) and subsequent clinical outcomes in a cohort of people with HIV (PWH) in routine care. Methods We conducted a retrospective chart review of PWH who initiated LA-CAB/RPV at Ward 86 in San Francisco through April 2024, censoring data on September 23, 2024.…